JPRN-jRCT2031210125招募中3 期
A prospective, open-label, multi-center, randomized, 52-week study evaluating the safety and efficacy of 0.02% STN1013900 ophthalmic solution alone or in combination with either 0.005% Latanoprost ophthalmic solution, or 0.5%Timolol ophthalmic solution in subjects with open angle glaucoma or ocular hypertension
Sakamoto Kayoko0 个研究点目标入组 150 人开始时间: 2021年5月31日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •20 years of age or older
- •Diagnosis of POAG, NTG, pseudoexfoliative glaucoma, pigmentary glaucoma or OHT in both eyes
- •Best-corrected visual acuity (BCVA) +0.7 log MAR or better (>= 20/100 Snellen or >= 0.20 in decimal unit) in each eye
- •Willingness and ability to give signed informed consent and follow study instructions
排除标准
- •Ophthalmic:
- •Clinically significant ocular disease
- •History of angle closure glaucoma, or narrow angles
- •Previous glaucoma intraocular surgery
- •Refractive surgery in either eye
- •Ocular trauma
- •Ocular infection
- •Any corneal disease
- •Known hypersensitivity to any component of the study drugs, or to topical anesthetic
- •Clinically significant systemic disease
- •Participation in any investigational study within 30 days prior to screening
- •Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control
研究者
相似试验
进行中（未招募）
不适用
A phase I/II trial for evaluating both safety and preliminary efficacy of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patientsCrigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The urea cycle disorders are inborn errors of metabolism that affect the transfer of nitrogen into urea. There are six disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia, argininosuccinic aciduria and argininemiaMedDRA version: 17.0Level: LLTClassification code 10021601Term: Inborn error of metabolism NOSSystem Organ Class: 100000004850EUCTR2011-004074-28-GBPromethera Biosciences21
尚未招募
4 期
Paximusâ?¢ Randomized Controlled TrialCTRI/2019/05/018886Meril Life Sciences Pvt Ltd
尚未招募
2 期
comparative clinical trial to evaluate safety and efficacy of test drug plus standard of care and standard of care alone in COVID 19 Acute Respiratory Distress Syndrome (ARDS) patients with non-invasive ventilation.CTRI/2021/12/038778Reliance Life Sciences Pvt Ltd
进行中（未招募）
不适用
A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune?) replacing CNI in a standard care regimen of CNI, mycophenolate mofetil (MMF) and steroids in heart transplant patients - Heart STEUCTR2005-001183-31-BEF. Hoffmann-La Roche Ltd650
进行中（未招募）
不适用
A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune) replacing CNI in a standard care regimen of CNI, mycophenolate mofetil (MMF) and steroids in heart transplant patients - Heart STHeart TransplantEUCTR2005-001183-31-CZF. Hoffmann-La Roche Ltd650